These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group. Carbonell-Estrany X Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453 [TBL] [Abstract][Full Text] [Related]
44. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623 [TBL] [Abstract][Full Text] [Related]
45. Respiratory syncytial virus infection in adults. Falsey AR Semin Respir Crit Care Med; 2007 Apr; 28(2):171-81. PubMed ID: 17458771 [TBL] [Abstract][Full Text] [Related]
46. In the trenches: a pediatrician's perspective on prevention and treatment strategies for RSV disease. Frogel MP Manag Care; 2008 Nov; 17(11 Suppl 12):7-12, discussion 18-9. PubMed ID: 19097557 [TBL] [Abstract][Full Text] [Related]
49. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Openshaw PJ; Dean GS; Culley FJ Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S58-64; discussion S64-5. PubMed ID: 12671454 [TBL] [Abstract][Full Text] [Related]
50. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712 [TBL] [Abstract][Full Text] [Related]
54. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042 [TBL] [Abstract][Full Text] [Related]
55. Timing of bronchiolitis hospitalisations and respiratory syncytial virus immunoprophylaxis in non-metropolitan Western Australia. Moore HC; Keil AD; Richmond PC; Lehmann D Med J Aust; 2009 Nov; 191(10):574. PubMed ID: 19912095 [No Abstract] [Full Text] [Related]
56. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)]. Pin I; Pilenko C; Bost M Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622 [TBL] [Abstract][Full Text] [Related]
57. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776 [TBL] [Abstract][Full Text] [Related]
58. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB; Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184 [TBL] [Abstract][Full Text] [Related]